NCT03301220 2026-03-18
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Massachusetts General Hospital
Dana-Farber Cancer Institute
University of Miami
Eastern Cooperative Oncology Group
Regeneron Pharmaceuticals
University of Utah